Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (ARQT) partnered with gymnast Simone Biles to launch a campaign about seborrheic dermatitis and eczema treatment. The Skin to Believe In campaign features Biles discussing her use of ZORYVE foam for seborrheic dermatitis and ZORYVE cream for eczema. It encourages people with these conditions to discuss long-term, steroid-free topical treatment options with a doctor.
S&P Dow Jones Indices will rebalance the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 before the market opens on September 21, 2026, to keep each index aligned with its target market-cap range.
Dell Technologies, Palo Alto Networks, Arista Networks, and Sandisk will join the S&P 100, while NIKE, Honeywell Aerospace, Simon Property Group, and Colgate-Palmolive exit. Bloom Energy, Everpure, and Illumina will enter the S&P 500, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource, which move to the S&P SmallCap 600. Multiple constituents, including HubSpot, AGNC Investment, Corcept Therapeutics, Brinker International, Herc Holdings, Delek US Holdings, AXT, Arcutis Biotherapeutics, AtriCure, Capri Holdings, Boston Beer, and others shift among the S&P MidCap 400 and S&P SmallCap 600.
Arcutis Biotherapeutics (ARQT) granted an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees, effective September 1, 2026, as inducement awards under its 2022 Inducement Plan.
The RSUs vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to continued employment, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (ARQT) will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16, 2026.
Management will participate in a fireside chat on Wednesday, September 16, 2026, at 1:50 p.m. ET. A live webcast and replay will be available in the “Events” section of the company’s website, with replay access for 180 days after the conference.
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate of 143,500 restricted stock units and options to purchase 37,000 shares of common stock to 24 newly hired employees under its 2022 Inducement Plan, effective August 3, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments over four years, subject to continued employment. The stock options have a ten-year term, vest over four years with a one-year cliff then monthly vesting, and carry an exercise price of $25.94 per share, equal to the August 3, 2026 Nasdaq closing price.
Arcutis (Nasdaq: ARQT) reported Q2 2026 net product revenue of $129.9 million, up 59% year-over-year and 23% sequentially, driven by broader ZORYVE demand and improved gross-to-net pricing. Net income reached $15.0 million, or $0.11 per basic and diluted share, versus a net loss a year earlier.
The company raised its 2026 net product sales guidance to $525–$540 million from $480–$495 million and generated $12.6 million in operating cash flow, with $238.9 million in cash, equivalents, restricted cash, and marketable securities at June 30, 2026. ZORYVE revenues were led by foam 0.3% at $67.4 million, followed by cream 0.3% at $35.3 million, cream 0.15% at $24.2 million, and cream 0.05% at $2.9 million.
Arcutis highlighted multiple regulatory and pipeline milestones, including FDA approval to expand ZORYVE cream 0.3% to plaque psoriasis patients aged two and older, FDA acceptance of an sNDA for ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, completion of Phase 2 vitiligo trial enrollment, ongoing Phase 2 hidradenitis suppurativa studies, and a Phase 1a/1b trial of ARQ-234. The company also launched a virtual health platform, entered a partnership with an AI-enabled healthcare platform to support ZORYVE access, completed hiring a targeted primary care and pediatric sales team, added Chris Peetz to its Board, and obtained two new U.S. patents.
Arcutis Biotherapeutics (Nasdaq: ARQT) has appointed Christopher “Chris” Peetz to its Board of Directors, effective July 15, 2026. According to Arcutis, the company expects his strategic and operational experience to support its next phase of growth, including advancing and expanding the ZORYVE (roflumilast) franchise and pipeline.
Peetz is co-founder and chief executive officer of Mirum Pharmaceuticals and an entrepreneur-in-residence at Frazier Life Sciences. His career includes leadership roles at Flashlight Therapeutics, Tobira, Jennerex, Onyx Pharmaceuticals, LaSalle Corporate Finance, Abgenix, Solazyme, and board service at Alpine Immune Sciences.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update after U.S. markets close on Wednesday, August 5, 2026. The company will hold a conference call and webcast at 4:30 p.m. ET, with live and replay access available via the Events section of its investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported FDA acceptance of a supplemental New Drug Application for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3–24 months. The FDA set a PDUFA target action date of February 23, 2027.
The sNDA is backed by Phase 2 INTEGUMENT-INFANT and Phase 1 PK data in 3–24 month-olds, showing safety and efficacy over 4 weeks. ZORYVE 0.05% is once-daily, steroid-free and already approved for children aged 2–5 years.
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 61,000 restricted stock units (RSUs) to 9 newly hired employees under its 2022 Inducement Plan. The awards, approved by the Board’s Compensation Committee, were granted July 1, 2026 and will vest 25% annually over four years, following Nasdaq Listing Rule 5635(c)(4).